News

Articles

Lilly will cap insulin prices for patients with and without insurance at $35 per month.

Eli Lilly to Cap Out-Of-Pocket Insulin Costs at $35

Moderna and Merck’s investigational personalized mRNA cancer vaccine has been granted Breakthrough Therapy Designation by FDA. 

Investigational Personalized mRNA Cancer Vaccine Gains Breakthrough Therapy Designation from FDA

Naoki Okamura, Astellas’ current chief strategy officer, will take over the role from Kenji Yasukawa.

Astellas to Appoint New CEO and President

The definitive agreement will give AstraZeneca global rights to CinCor’s portfolio of cardiorenal disease treatments.

AstraZeneca Inks $1.8 Billion Acquisition for CinCor Pharma

Merck, known as MSD outside of the United States and Canada, will pay Kelun-Biotech up to $9l3 billion for seven early-stage oncology treatments.

Merck Licenses Kelun-Biotech ADC’s in Deal Worth $9.3 Billion

GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.

GSK and Wave Life Sciences to Collaborate on Oligonucleotide Therapeutics

Amgen’s $27.8 billion acquisition of Horizon Therapeutics, an Irish biotechnology company, is one of the largest of 2022.

Amgen Inks $27.8 Billion Blockbuster to Acquire Horizon Therapeutics

Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.

Eisai and BioGen Alzheimer’s Drug Shows Promising Results in Phase III Study

AstraZeneca inked a deal worth up to $320 million to purchase Neogene Therapeutics, a biotech start-up focused on T-cell receptor therapies.

AstraZeneca Acquires Neogene Therapeutics for $320 Million

CSL’s Hemgenix (etranacogene dezaparvovec) will cost approximately $3.5 million, making it the most expensive single-use medicine in the United States.

Top News